Australia Dermatology Devices Market Size & Outlook, 2025-2033
Australia Dermatology Devices Market Insights
- According to Reed Intelligence analysis, the Australia Dermatology Devices Market size was USD 124.35 Million in 2024 and is projected to reach USD 327.65 Million by 2033.
- The Australia market is projected to grow at a CAGR of 11.44% between 2026 and 2033.
- By segment, Diagnostic Device emerged as the largest By Product Type in terms of market size in 2024.
- Treatment Device is anticipated to remain the most attractive By Product Type segment, recording the fastest growth during the forecast period.
![Australia Dermatology Devices Market Size, Share & Growth Report By [2033]](https://reedintelligence.com/uploads/charts/australia-dermatology-devices-market-australia-by-product-type-38627.png)
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- As of 2024, Australia held 0.81% of the global Dermatology Devices Market size.
- By 2033, United States is anticipated to capture the largest share of the global Dermatology Devices Market.
- In Asia Pacific, China is expected to lead the regional Dermatology Devices Market size by 2033.
- Taiwan will remain the fastest-growing market in Asia Pacific, reaching USD 340.09 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 124.35 Million |
| Market Size In 2033 | USD 327.65 Million |
| Largest segment | Diagnostic Device |
| Units | Revenue in USD Million |
| CAGR | 11.44% (2025-2033) |
| Segmnetation Covered | |
| By Product Type |
|
| By Application |
|
| By End User |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Australia Dermatology Devices Market By Product Type 2025-2033 (USD Million)
| By Product Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostic Device | XX.x | XX.x | XX.x | 73.83 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Treatment Device | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Australia Dermatology Devices Market By Application 2025-2033 (USD Million)
| By Application | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Skin Cancer Diagnosis | XX.x | XX.x | XX.x | 37.34 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Acne | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Psoriasis | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Skin Rejuvenation | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Warts | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Australia Dermatology Devices Market By End User 2025-2033 (USD Million)
| By End User | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 58.79 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Private Clinics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Specialty Dermatology Clinics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
